This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Noth, I. Articles by Martinez, F. J. Search for Related Content PubMed PubMed Citation Articles by Noth, I. Articles by Martinez, F. J.

Recent Advances in Idiopathic Pulmonary Fibrosis^*

^* From the Section of Pulmonary and Critical Care Medicine (Dr. Noth), University of Chicago, Chicago, IL; and the Division of Pulmonary and Critical Care Medicine (Dr. Martinez), University of Michigan Health System, Ann Arbor, MI.

Correspondence to: Imre Noth, MD, FCCP, University of Chicago, Pulmonary and Critical Care, 5841 S Maryland Ave, MC6076, Chicago, IL 60637; e-mail: inoth{at}medicine.bsd.uchicago.edu

Abstract

Idiopathic pulmonary fibrosis (IPF) remains the most common of the idiopathic interstitial pneumonias and portends a poor prognosis. Significant strides have been made in the approach to diagnosis and in the ability to predict outcome in the last few years. Advances in high-resolution CT (HRCT) scanning have allowed an accurate diagnosis obviating the need for surgical biopsy in many patients. Furthermore, HRCT scanning may aid in determining prognosis and identifying disease progression. The appropriate use of the HRCT scan requires a multidisciplinary iterative approach incorporating all available data to reach a final diagnosis. However, there remains great heterogeneity in disease progression. Pulmonary hypertension and acute exacerbations of IPF negatively influence prognosis and are increasingly a target of therapy. There has been an increase in the number of well-designed clinical trials of IPF that have focused on more specific targets. While no cure has yet been found, each trial expands our understanding regarding the natural course of the disease and the impact of targeted therapy. In the interim, lung transplantation, which appears to improve survival in a subset of IPF patients, remains the only intervention. The objective of this article is to review advances in the understanding of IPF and the evidence for the findings outlined above.

Key Words: acute exacerbation of idiopathic pulmonary fibrosis • diagnosis • idiopathic interstitial pneumonitis • idiopathic pulmonary fibrosis • idiopathic pulmonary fibrosis clinical research network • nonspecific interstitial pneumonia • pulmonary arterial hypertension • therapy • usual interstitial pneumonia

This article has been cited by other articles:

				J. M. Reich, I. Noth, and F. J. Martinez Genesis of Some Histologic, BAL, and Auscultatory Features of Idiopathic Pulmonary Fibrosis Chest, February 1, 2008; 133(2): 585 - 586. [Full Text] [PDF]